Business Context and Reporting Period
This Form 8-K was filed by DanDrit Biotech USA, Inc. on April 4, 2016. The filing reports the entry into a Material Definitive Agreement to acquire assets and liabilities of OncoSynergy, Inc., a privately-held Delaware corporation developing novel oncology drug candidates. The transaction is structured as an asset purchase agreement.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. The primary financial terms disclosed relate to the acquisition structure:
- Consideration: The purchase price consists of "Consideration Shares" equal to the number of shares of Common Stock outstanding immediately prior to closing, plus derivative securities of like tenor.
- Ownership Impact: Immediately following closing, OncoSynergy will hold 50% of the Company's capital stock on a fully diluted basis.
- Capital Requirement: The acquisition is conditioned on each party (the Company and OncoSynergy) receiving equity capital of not less than $3.0 million.
Material Changes
The material change reported is the execution of the Asset Purchase Agreement dated April 4, 2016. Key changes include:
- Acquisition of OncoSynergy's assets and liabilities.
- Issuance of unregistered equity securities (Consideration Shares) to OncoSynergy pursuant to Section 4(a)(2) of the Securities Act of 1933.
- Employment offers to certain OncoSynergy employees.
- Planned change of the Company's name following shareholder approval.
Guidance, Outlook, and Risks
Conditions Precedent: The transaction is subject to shareholder approval and the receipt of the required $3.0 million equity capital by both entities.
Timeline: The acquisition must be completed by October 31, 2016, unless otherwise agreed.
Risks: The transaction is contingent on closing conditions; failure to meet these conditions could prevent the acquisition. The filing notes that representations and warranties are subject to qualifications and limitations.
Investor Verification Checklist
- Verify the status of the required $3.0 million equity capital raise for both DanDrit Biotech USA, Inc. and OncoSynergy, Inc.
- Confirm the outcome of the shareholder vote required to approve the acquisition and name change.
- Review the full Asset Purchase Agreement (Exhibit 10.1) for specific liabilities being assumed and detailed terms of the derivative securities.
- Monitor the October 31, 2016 deadline for the completion of the transaction.